Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. We are leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-
metabolic, hepatic infectious, and central nervous system diseases with unmet need. Our first medicine, the first-ever RNAi therapeutic, has recently been approved by the FDA in the US for the treatment of the polyneuropathy of hereditary transthyretin-
mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy.
In addition, Alnylam has four investigational medicines in late-stage development.
The Market Insights Lead for CEMEA provides high quality insights on the patient experience, market environment and brand perception in a variety of orphan and rare diseases.
The insights will be based on primary and secondary market research, publicly available brand and market information, and non-
publicly available patient, stakeholder, brand and market intelligence. The candidate should be sufficiently knowledgeable in each of these areas with the goal to bring together and interpret matters to provide insight into business performance.
The Market Insights Lead reports to the Director CEMEA Market Insights & Forecasting; this position will be based in Maidenhead, UK.
Summary of Key Responsibilities